(Q40651062)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9267484%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

title

Paclitaxel activity in anthracycline refractory breast cancer patients (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9267484%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

Paclitaxel Activity in Anthracycline Refractory Breast Cancer Patients (English)

1 reference

https://api.crossref.org/works/10.1177/030089169708300307

12 November 2024

1 reference

P. Vici

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9267484

12 November 2024

L. Di Lauro

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9267484

12 November 2024

F. Conti

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9267484

12 November 2024

E. Capomolla

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9267484

12 November 2024

T. Gionfra

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9267484

12 November 2024

A. Amodio

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9267484

12 November 2024

M. Lopez

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9267484

12 November 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=9267484

12 November 2024

publication date

1 May 1997

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9267484%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

May 1997

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=9267484

full work available at URL

12 November 2024

https://journals.sagepub.com/doi/pdf/10.1177/030089169708300307

1 reference

https://api.crossref.org/works/10.1177/030089169708300307

https://journals.sagepub.com/doi/pdf/10.1177/030089169708300307

12 November 2024

1 reference

https://api.crossref.org/works/10.1177/030089169708300307

12 November 2024

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9267484%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

volume

83

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9267484%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9267484%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

page(s)

661-664

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9267484%20AND%20SRC:MED&resulttype=core&format=json

Paclitaxel activity in heavily pretreated breast cancer: a National Cancer Institute Treatment Referral Center trial

5 November 2019

cites work

1

1 reference

https://api.crossref.org/works/10.1177/030089169708300307

Taxol-requiring mutant of Chinese hamster ovary cells with impaired mitotic spindle assembly

12 November 2024

3

1 reference

https://api.crossref.org/works/10.1177/030089169708300307

Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients.

12 November 2024

5

1 reference

https://api.crossref.org/works/10.1177/030089169708300307

A phase II study of paclitaxel in advanced breast cancer resistant to anthracyclines

12 November 2024

10

1 reference

https://api.crossref.org/works/10.1177/030089169708300307

12 November 2024

Cancer Treatment Reports

12

69

515

Gupta R.S.

1985

1 reference

https://api.crossref.org/works/10.1177/030089169708300307

Phase II Trial of Taxol, an Active Drug in the Treatment of Metastatic Breast Cancer

12 November 2024

14

1 reference

https://api.crossref.org/works/10.1177/030089169708300307

Nonparametric Estimation from Incomplete Observations

12 November 2024

15

1 reference

https://api.crossref.org/works/10.1177/030089169708300307

Taxol: an antimitotic agent with a new mechanism of action

12 November 2024

16

1 reference

https://api.crossref.org/works/10.1177/030089169708300307

Reporting results of cancer treatment

12 November 2024

18

1 reference

https://api.crossref.org/works/10.1177/030089169708300307

Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer

12 November 2024

19

1 reference

https://api.crossref.org/works/10.1177/030089169708300307

Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer

12 November 2024

20

1 reference

https://api.crossref.org/works/10.1177/030089169708300307

Prediction of doxorubicin resistance in vitro in myeloma, lymphoma, and breast cancer by P-glycoprotein staining

12 November 2024

21

1 reference

https://api.crossref.org/works/10.1177/030089169708300307

Expression of P-glycoprotein in breast cancer tissue and in vitro resistance to doxorubicin and vincristine

12 November 2024

22

1 reference

https://api.crossref.org/works/10.1177/030089169708300307

Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response

12 November 2024

24

1 reference

https://api.crossref.org/works/10.1177/030089169708300307

Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer

12 November 2024

25

1 reference

https://api.crossref.org/works/10.1177/030089169708300307

Measurement of cremophor EL following taxol: plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistant phenotype

12 November 2024

26

1 reference

https://api.crossref.org/works/10.1177/030089169708300307

12 November 2024

Identifiers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9267484%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

1 reference